-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study
(2215) Views (439) Full article downloads
Authors: Gian Luigi Marseglia, Mariangela Tosca, Ignazio Cirillo, Amelia Licari, Maddalena Leone, Alessia Marseglia, Anna Maria Castellazzi, Giorgio Ciprandi
Published Date February 2007
Volume 2007:3(1) Pages 13 - 17
DOI: http://dx.doi.org/10.2147/TCRM.S
Gian Luigi Marseglia1, Mariangela Tosca2, Ignazio Cirillo3, Amelia Licari1, Maddalena Leone1, Alessia Marseglia1, Anna Maria Castellazzi1, Giorgio Ciprandi4
1Dipartimento di Scienze Pediatriche, Università degli Studi di Pavia, Pavia, Italy; 2Centro Malattie Allergiche, Istituto G. Gaslini, Genova, Italy; 3Ospedale Marina Militare, La Spezia, Italy; 4Semeitoica Medica IDipartimento di Medicina Interna, Azienda Ospedale-Università San Martino di Genova, Genova, Italy
Abstract: Probiotic milk has been previously demonstrated to reduce the number of respiratory infections (RI) among children attending day care centres. Thus, this pilot study was aimed to assess the efficacy and the safety of 3 month treatment with Bacillus clausii in the prevention of recurrent respiratory infections (RRI) in children. Eighty children with RRI were studied: 40 of them were randomly treated with B. clausii for 3 months, and followed up for further 3 months; 40 were included in the control group during the same period. Children treated with B. clausii had shorter duration of RI in comparison with the control group both during the treatment phase (mean 11.7 days vs 14.37; p=0.037) and the follow-up period (mean 6.6 days vs 10.92; p=0.049). This effect was evident also in allergic children during the follow-up. In conclusion, this pilot study provides the first preliminary evidence that B. clausii may exert a significant and persistent impact on RI in children and is safe and well tolerated.
Keywords: probiotic, children, respiratory infections, allergy
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- Tenofovir-associated bone density loss
- The benefits and risks of testosterone replacement therapy: a review
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




